What are the risks of rivaroxaban and dabigatran use in Asians with nonvalvular atrial fibrillation?
The thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran use in Asians with nonvalvular atrial fibrillation were studied in a 2016 study published in the Journal of the American College of Cardiology. The authors found that rivaroxaban was associated with a lower risk of stroke and systemic embolism, compared with dabigatran, but had a higher risk of major bleeding. The study also showed that dabigatran was associated with a lower risk of all-cause mortality, compared with rivaroxaban.